Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172348 | 0.90 | GRM5 (0.67) | GRM5KCNH2DGAT1PKM | |
| SCHEMBL4184538 | 0.88 | GRM5 (0.59) | GRM5KCNH2GAAMAPTTSHR | |
| SCHEMBL4167366 | 0.86 | GRM5 (0.71) | GRM5KCNH2DGAT1PKM | |
| SCHEMBL2895291 | 0.85 | GRM5 (0.73) | GRM5KCNH2MAPK1PKM | |
| SCHEMBL2895780 | 0.85 | GRM5 (0.73) | GRM5KCNH2MAPK1PKM | |
| SCHEMBL2895294 | 0.85 | GRM5 (0.73) | GRM5KCNH2MAPK1PKM | |
| SCHEMBL2889851 | 0.83 | GRM5 (0.71) | GRM5KCNH2PKM | |
| SCHEMBL5482144 | 0.83 | GRM5 (0.71) | GRM5KCNH2PKM | |
| SCHEMBL5482911 | 0.81 | GRM5 (0.71) | GRM5KCNH2MAPT | |
| SCHEMBL2895056 | 0.81 | GRM5 (0.71) | GRM5KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 1573/4885DGAT1 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.